Text Size

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study

Hori Y, Oka K, Inai M.


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Toho University Omori Medical Center, Toho University Graduate School of Medicine, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan; Global Clinical Development and Operations, Product Development Division, Clinical Operations Japan/Asia, Santen Pharmaceutical Co., Ltd., Kita-ku, Ofukacho Osaka, Japan

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022